Olaparib for Metastatic Breast Cancer

Not currently recruiting at 22 trial locations

Overseen By Nadine Tung, MD

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Beth Israel Deaconess Medical Center

Must not be taking: PARP inhibitors, CYP3A inhibitors

Disqualifiers: BRCA1/2 mutation, Brain metastases, MDS/AML, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 2 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 6

Duration: 24 weeks

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a drug called olaparib (also known as Lynparza) for effectiveness against metastatic breast cancer with specific genetic mutations. Metastatic breast cancer has spread beyond the breast, and certain genetic changes can hinder the cancer's ability to repair its DNA, potentially making it more susceptible to olaparib. Participants must have confirmed stage IV breast cancer and genetic testing showing specific mutations in DNA repair genes, excluding BRCA1 or BRCA2 genes. The trial aims to determine if olaparib can effectively treat these genetic mutations in breast cancer. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Will I have to stop taking my current medications?

The trial requires a washout period (time without taking certain medications) for some drugs. You must stop taking strong or moderate CYP3A inhibitors and inducers before starting the study, with a washout period of 2 to 5 weeks depending on the specific medication. Other medications may be allowed, but it's best to discuss your current medications with the study team.

Is there any evidence suggesting that olaparib is likely to be safe for humans?

Research has shown that olaparib, a drug tested for advanced breast cancer, has promising safety results. In earlier studies with patients who have BRCA-mutated cancers, olaparib was generally well-tolerated. Specifically, one study found that 52% of people taking olaparib experienced less cancer growth or spreading compared to only 23% of those on certain chemotherapy treatments.

Like any medication, olaparib can cause side effects. However, its use in treating other cancers, such as ovarian cancer, has provided more safety information. This suggests that olaparib is generally safe, though individual experiences may vary. Participants in trials should discuss potential risks and benefits with their healthcare providers. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising for metastatic breast cancer?

Researchers are excited about Olaparib for metastatic breast cancer because it offers a unique approach by targeting specific genetic mutations, known as germline and somatic mutations. Unlike traditional chemotherapy that affects all dividing cells, Olaparib is a PARP inhibitor, which works by preventing cancer cells with these mutations from repairing their DNA, leading to cell death. This targeted mechanism not only aims to be more effective against certain types of cancer cells but also potentially reduces side effects compared to more generalized treatments.

What evidence suggests that olaparib might be an effective treatment for metastatic breast cancer?

Research has shown that olaparib can help treat metastatic breast cancer. In studies, olaparib reduced the risk of cancer growth, spread, or death by 42% compared to some chemotherapy treatments. About 52% of people taking olaparib experienced these benefits, while only 23% did with chemotherapy. It also helped patients live longer without their cancer worsening. In another study, 9% of patients on olaparib had a complete response, showing no signs of cancer. These findings suggest that olaparib could be a strong option for treating metastatic breast cancer. Participants in this trial will receive olaparib, with different arms studying its effects on germline and somatic mutations. ^{2 3 6 7 8}

Who Is on the Research Team?

Nadine Tung, MD

Principal Investigator

Beth Israel Deaconess Medical Center

Are You a Good Fit for This Trial?

This trial is for adults with metastatic breast cancer that has spread beyond the breast and have specific gene mutations (excluding BRCA1/2). Participants must have normal organ/bone marrow function, no more than two prior chemotherapy regimens for metastasis, not be pregnant or breastfeeding, able to take oral medication, and willing to follow study procedures.

Inclusion Criteria

My breast cancer is at stage IV and has been confirmed by tests.

I have a genetic mutation in a DNA repair gene, but not in BRCA1 or BRCA2.

I have not failed more than two chemotherapy treatments for my advanced cancer.

Exclusion Criteria

Pregnant or breast feeding women.

I haven't had cancer in the last 5 years, except for certain types that were fully treated.

I have not had major surgery in the last 2 weeks.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Olaparib monotherapy in 21-day cycles, taking the drug twice daily

24 weeks

Tumor measurements every 6 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

36 months

What Are the Treatments Tested in This Trial?

Interventions

• Olaparib

Trial Overview

The trial tests Olaparib's effectiveness in patients whose tumors are sensitive due to certain genetic mutations. Olaparib is a PARP inhibitor which may help treat cancer by exploiting the tumor's impaired DNA repair ability. The study includes those with inherited or tumor-only mutations.

How Is the Trial Designed?

Group I: OLAPARIB QD SOMATIC MUTATION - EXPANSION Experimental Treatment 1 Intervention

After the screening procedures confirm eligibility to participate in the research study: * Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart. * Tumor measurements q6 weeks x 24 weeks, then q 12 weeks

Group II: OLAPARIB QD SOMATIC MUTATION Experimental Treatment 1 Intervention

After the screening procedures confirm eligibility to participate in the research study: * Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart. * Tumor measurements q6 weeks x 24 weeks, then q 12 weeks

Group III: OLAPARIB QD GERMLINE MUTATION - EXPANSION Experimental Treatment 1 Intervention

After the screening procedures confirm eligibility to participate in the research study: * Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart. * Tumor measurement q6 weeks x 24 weeks, then q 12 weeks

Group IV: OLAPARIB QD GERMLINE MUTATION Experimental Treatment 1 Intervention

After the screening procedures confirm eligibility to participate in the research study: * Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart. * Tumor measurement q6 weeks x 24 weeks, then q 12 weeks

Olaparib is already approved in European Union, United States for the following indications:

Approved in European Union as Lynparza for:

• Breast cancer
• Ovarian cancer
• Fallopian tube cancer
• Peritoneal cancer
• Pancreatic cancer
• Prostate cancer
• Endometrial cancer

Approved in United States as Lynparza for:

• Ovarian, fallopian tube, and primary peritoneal cancer
• Breast cancer
• Prostate cancer
• Pancreatic cancer

Who Is Running the Clinical Trial?

Beth Israel Deaconess Medical Center

Lead Sponsor

Trials

872

Recruited

12,930,000+

Johns Hopkins University

Collaborator

Trials

2,366

Recruited

15,160,000+

AstraZeneca

Industry Sponsor

Trials

4,491

Recruited

290,540,000+

Sir Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Dr. Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Dana-Farber Cancer Institute

Collaborator

Trials

1,128

Recruited

382,000+

Published Research Related to This Trial

In a Phase I study involving 28 Japanese patients with advanced solid tumors, olaparib tablets at doses of 200 and 300 mg twice daily were found to be tolerable, with no dose-limiting toxicities reported.

The most common side effects included nausea, decreased appetite, anemia, and constipation, but no confirmed antitumor responses were observed, leading to the selection of 300 mg bid as the recommended dose for future studies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours. Yonemori, K., Tamura, K., Kodaira, M., et al.[2022]

Olaparib is particularly effective for patients with BRCA-mutated ovarian cancer, but it also benefits a subset of patients with BRCA wild-type tumors that have loss-of-function mutations in DNA repair genes, showing similar treatment outcomes.

The study suggests that patients with specific HRR gene mutations, even without BRCA mutations, can be identified as a group that may respond well to olaparib, indicating a potential for broader use of this treatment in ovarian cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. Hodgson, DR., Dougherty, BA., Lai, Z., et al.[2020]

Olaparib significantly improves overall survival in patients with recurrent platinum-sensitive ovarian cancer, with a hazard ratio of 1.24 based on a meta-analysis of 7 randomized controlled trials involving 2406 patients.

However, the treatment is associated with a higher incidence of adverse events, particularly for grades 3 or higher, indicating that while olaparib is effective, it also carries a risk of significant side effects.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer. Chen, Q., Li, X., Zhang, Z., et al.[2022]

Olaparib, a PARP inhibitor, has shown significant clinical benefits in improving progression-free survival for patients with BRCA1 or BRCA2 mutated HER2 negative metastatic breast cancer compared to standard chemotherapy.

The drug has a manageable safety profile, making it a promising treatment option, particularly for triple negative breast cancer, although further research is needed to optimize its use with other therapies and identify suitable biomarkers.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Olaparib for the treatment of breast cancer. Griguolo, G., Dieci, MV., Guarneri, V., et al.[2019]

Olaparib, a PARP inhibitor, showed a 36% objective response rate in women with relapsed ovarian cancer and a germline BRCA1/2 mutation, even after they had undergone multiple lines of chemotherapy, indicating its efficacy in this challenging patient population.

The median duration of response to olaparib was 7.4 months, and the safety profile was consistent across patients who had received three or more lines of prior chemotherapy, with similar rates of serious adverse events.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. Matulonis, UA., Penson, RT., Domchek, SM., et al.[2022]

Olaparib (Lynparza) is approved for treating adult patients with high-risk early breast cancer that has a germline BRCA mutation, following chemotherapy treatment.

This approval highlights Olaparib's role as an adjuvant therapy, which means it is used after initial treatments to help prevent cancer recurrence.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

New Adjuvant Treatment for High-Risk Early Breast Cancer. Aschenbrenner, DS.[2022]

Olaparib is an effective oral treatment for patients with BRCA mutation-positive ovarian cancer, approved for maintenance therapy after platinum-based chemotherapy, showing good tolerability with common side effects like nausea, fatigue, and anemia being mild to moderate.

Long-term monitoring is recommended due to a low risk of serious hematological complications, such as anemia and myelodysplastic syndrome, ensuring patient safety during treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety evaluation of olaparib for treating ovarian cancer. Lheureux, S., Bowering, V., Karakasis, K., et al.[2015]

Citations

1.

lynparza.com

lynparza.com/breast-cancer/results/metastatic-breast-cancer.html

Metastatic Breast Cancer - Clinical Study Results of ...

LYNPARZA lowered the risk of cancer growing or spreading, or death by 42% compared with certain chemotherapies. 52% of people who took LYNPARZA and 23% of ...

2.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC6503629/

OlympiAD final overall survival and tolerability results

In the OlympiAD study, olaparib was shown to improve progression-free survival compared with chemotherapy treatment of physician's choice (TPC) in patients ...

3.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/39544591/

Real-World Clinical Outcomes of Treatment With Olaparib ...

Our data showed that olaparib is effective in the real world. The incidence of neutropenia seemed higher in Japanese patients. Keywords: brca ...

4.

astrazeneca-us.com

astrazeneca-us.com/media/press-releases/2024/lynparza-demonstrated-clinically-meaningful-prolonged-survival-benefit-in-early-breast-cancer-in-olympia-phase-iii-trial.html

LYNPARZA® (olaparib) demonstrated clinically meaningful ...

LYNPARZA reduced the risk of invasive breast cancer recurrence, second cancers or death by 35% (HR 0.65; 95% CI; 0.53-0.78) and reduced the risk ...

5.

nejm.org

nejm.org/doi/full/10.1056/NEJMoa1706450

Olaparib for Metastatic Breast Cancer in Patients with a ...

A complete response was seen in 9.0% of the patients who had measurable disease in the olaparib group and in 1.5% in the standard-therapy group.

6.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC10948524/

Clinical effectiveness and safety of olaparib in BRCA-mutated ...

The interim analysis of the phase IIIb LUCY trial demonstrated the clinical effectiveness of olaparib in patients with germline BRCA-mutated ...

7.

lynparzahcp.com

lynparzahcp.com/breast-cancer/safety-tolerability/olympiad.html

gBRCAm, HER2-Negative, Metastatic Breast Cancer

Learn about the safety and tolerability for LYNPARZA® (olaparib) in the OlympiAD trial for patients with gBRCAm, HER2-negative, metastatic breast cancer.

8.

bigagainstbreastcancer.org

bigagainstbreastcancer.org/new-data-confirms-olaparibs-survival-benefits-in-early-breast-cancer/

new data confirms olaparib's survival benefits in early ...

Survival rates at six years were 87.5% for olaparib patients versus 83.2% for those on placebo. 35% Reduced risk of events: Olaparib reduced the ...